Abbvie Inc. (ABBV) has announced various strategic actions. It has reported
record earnings and declared a
quarterly dividend of $1.64, yielding 3.4%. Several potential investors, including Roxbury Financial LLC and BXM Wealth LLC, have taken positions in the company. The company has reported positive
financial results for the full year and Q4 2024. Moreover, the leadership change with appointment of
CEO Robert A. Michael as Chairman of the Board has taken place. AbbVie showed its commitment to innovation through its collaboration with Regenxbio on the
ABBV-RGX-314 clinical programme, and a major investment of $52M in Xilio's revolutionary technology. The acquisition of
Nimble Therapeutics indicates strengthening of immunology pipeline. AbbVie has also garnered increased buy-side interest, with several institutional investors bolstering their holdings. Its stocks have gained as much as 9.4% over a week's time. Finally, the
US FDA's approval of AbbVie-Pfizer's treatment for intra-abdominal infections is a significant milestone.
Abbvie ABBV News Analytics from Mon, 28 Oct 2024 07:00:00 GMT to Sat, 15 Feb 2025 13:12:54 GMT -
Rating 7
- Innovation 5
- Information 8
- Rumor -2
